N@N

EPICEPT CORP (NASDAQ:EPCT), Down By 31.60% ($0.16) From $0.500 After BUYINS.NET Report Predicted Weakness After Earnings

^{Published on 2011-09-12 15:46:28 - WOPRAI}
 

September 12, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Friday, August 12th 2011 stating that EPICEPT CORP (NASDAQ:EPCT) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=epct&id=185938

At the time this story was written, EPICEPT CORP (NASDAQ:EPCT) is Down By 31.60% ($0.16) From $0.500 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

EPICEPT CORP (NASDAQ:EPCT) - EpiCept Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of cancer and pain in the United States and Germany. Its lead product, Ceplene, is used for the treatment of acute myeloid leukemia. The companys cancer portfolio includes Crinobulin, a small molecule vascular disruption agent (VDA) and apoptosis inducer, which is completed Phase I clinical trial for the treatment of patients with solid tumors; and Azixa, an apoptosis inducer under Phase II clinical trial product to treat the patients with primary glioblastoma and melanoma that has metastasized to the brain and non-small-cell lung cancer that has spread to the brain. Its late-stage pain product candidate, EpiCept NP-1 cream, is a prescription topical analgesic cream, which concluded a Phase II clinical trial designed to provide long-term relief of pain associated with peripheral neuropathies. The company also offers LidoPAIN BP, a prescription analgesic non-sterile patch designed to provide sustained topical delivery of lidocaine for the treatment of acute or recurrent lower back pain. It has license agreements with Meda AB; DURECT Corporation; Myriad Pharmaceuticals, Inc.; and Endo Pharmaceuticals Inc. EpiCept Corporation was formerly a subsidiary of Epic Resorts LLC. The company was founded in 1993 and is based in Tarrytown, New York.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. EPICEPT CORP (NASDAQ:EPCT) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net